The study will be aimed at adult individuals of both sexes who have undergone BGYR reductive gastroplasty, both by the Unified Health System (SUS) and by private institutions, residents of the Federal District and surroundings. Descriptors: Bariatric surgery, nutritional status, energy metabolism, obesity.
Conditions
Interventions
Participants will be allocated randomly into four groups, each composed of 25 volunteers, being: Group 1 - constituted by patients submitted to qualitative dietary guidance associated with a resistanc
Group 2 - composed of patients submitted to qualitative dietary guidance and protein supplementation associated with a resistance training program
Group 3 - consisting of patients who will receive qualitative dietary guidance and protein supplementation associated with the orientation of the practice of conventional physical activity
and Group 4 (control) - composed of patients who will receive only a qualitative dietary orientation and the practice of conventional physical activity. Allocation of patients in the study groups will
food consumption questionnaires (24-hour reminders), to obtain information on caloric and protein intake and necessary guidelines
to perform a physical evaluation and the following tests to evaluate body composition, muscle strength and blood: X-ray absorptiometry (DXA)
peak of isokinetic torque, electrical bioimpedance
body weight
stature
estimation of energy expenditure at rest through indirect calorimetry
and to collect blood (10mL), per qualified professional, for glucose, total cholesterol, HDL-c, LDL-c, VLDL-c, triglycerides, ultra-sensitive C-reactive protein, interleukin-6, interleukin-10, tumor n
Dietary supplement
Other
E02.760.169.063.500.387.875
SP6.051.227
Sponsors
Universidade de Brasília
Universidade de Brasília
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients who underwent bariatric surgery (BPYR) for at least 24 months will be included; aged between 18 and 60 years.
Exclusion criteria
Exclusion criteria: Patients with diabetes mellitus, pacemaker, decompensated thyroid dysfunction, or who present in the postoperative period malignant or consumptive disease (neoplasms, AIDS, liver diseases, nephropathies, heart failure and degenerative diseases), psychiatric disorders using psychotropic drugs, chronic use of corticosteroids, hormone therapy or medication for weight loss, presence of amputation and gestation, and patients who were on regular use of the protein supplement for less than 2 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean difference of fat-free mass of at least 5% evaluated by dual-energy X-ray absorptiometry (DEXA) after 6 months of intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean difference in muscle strength of at least 10% evaluated by the isokinetic dynamometer and manual pre and post-intervention force.;Increased resting energy expenditure by 5% as assessed by dual-energy X-ray absorptiometry (DEXA) and multifrequency bioimpedance before and after the intervention. | — |
Countries
Brazil
Contacts
Public ContactFernando;Kênia Pardo;Baiocchi de Carvalho
Universidade de Brasília;Universidade de Brasília
Outcome results
None listed